Stock Library / WST

WST Healthcare Latest YouTube: Q2 2026 Published 2026-07-23

West Pharmaceutical Services, Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

West Pharmaceutical Stock: It Beat & RAISED on the GLP-1 Boom — Is WST a Buy Now?

Published 2026-07-23

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked

4

Episodes linked

4

Latest video

Q2 2026

2026-07-23

Podcast available

Yes

Current price

$353.08

-3.85 (-1.08%)

Trailing / Forward P/E

45.27x

Forward: 35.43x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

13.8%

Earnings: 18.1%

Margins

22.5% op

Gross: 36.8% · Net: 17.0%

Balance sheet

2.82x current

Debt / Equity: 10.6

52-week range / Beta

$223.83 - $386.00

Beta: 1.14

Analyst target

$404.73

Upside: 14.6%

Cash / shareholder return

1.12% FCF yield

Dividend yield: 0.25%

Company context

Industry: Medical Instruments & Supplies

Country: United States

Employees: —

Price to book: 8.31x

Return on equity: 19.1%

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Price chart

Market context for WST

Competitive view

WST vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

West Pharmaceutical Services, Inc. latest YouTube video thumbnail

West Pharmaceutical Services, Inc.

WST

YouTube Spotify Podbean

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Intuitive Surgical latest YouTube video thumbnail

Intuitive Surgical

ISRG

YouTube Spotify Podbean Apple

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Johnson & Johnson latest YouTube video thumbnail

Johnson & Johnson

JNJ

YouTube Podbean Apple

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

WST

$24.85B

West Pharmaceutical Services, Inc.

ISRG

$135.72B

Intuitive Surgical

JNJ

$651.25B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

WST

45.3x

West Pharmaceutical Services, Inc.

ISRG

43.5x

Intuitive Surgical

JNJ

31.4x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

WST

35.4x

West Pharmaceutical Services, Inc.

ISRG

31.4x

Intuitive Surgical

JNJ

22.0x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

WST

13.8%

West Pharmaceutical Services, Inc.

ISRG

18.5%

Intuitive Surgical

JNJ

6.6%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

WST

18.1%

West Pharmaceutical Services, Inc.

ISRG

26.5%

Intuitive Surgical

JNJ

-0.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

WST

22.5%

West Pharmaceutical Services, Inc.

ISRG

33.6%

Intuitive Surgical

JNJ

29.2%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

WST

36.8%

West Pharmaceutical Services, Inc.

ISRG

66.7%

Intuitive Surgical

JNJ

68.1%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

WST

17.0%

West Pharmaceutical Services, Inc.

ISRG

28.4%

Intuitive Surgical

JNJ

21.5%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

WST

19.1%

West Pharmaceutical Services, Inc.

ISRG

17.4%

Intuitive Surgical

JNJ

25.7%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

WST

1.1%

West Pharmaceutical Services, Inc.

ISRG

1.9%

Intuitive Surgical

JNJ

2.6%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

WST

10.59x

West Pharmaceutical Services, Inc.

ISRG

—

Intuitive Surgical

JNJ

57.71x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

WST

2.82x

West Pharmaceutical Services, Inc.

ISRG

4.96x

Intuitive Surgical

JNJ

1.09x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

WST

1.14

West Pharmaceutical Services, Inc.

ISRG

1.46

Intuitive Surgical

JNJ

0.23

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

WST

0.2%

West Pharmaceutical Services, Inc.

ISRG

—

Intuitive Surgical

JNJ

2.0%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

WST

14.6%

West Pharmaceutical Services, Inc.

ISRG

26.2%

Intuitive Surgical

JNJ

0.8%

Johnson & Johnson

Related research

Non-quarter videos featuring WST

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-07-23

West Pharma (WST): Beat & Raised on the GLP-1 Boom — Still a HOLD? #Shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for WST

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-07-23

Published youtube podcast complete

West Pharmaceutical Stock: It Beat & RAISED on the GLP-1 Boom — Is WST a Buy Now?

Quarterly earnings-analysis entry for West Pharmaceutical Services, Inc.. Use the links on the right to open the video or podcast episode.

YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music

Q1 2026

Episode live

2026-04-26

Published youtube complete

WST Stock: EPS Beats by 27% — Q1 2026 Earnings Analysis

Quarterly earnings-analysis entry for West Pharmaceutical Services, Inc.. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podbean Show Apple Podcasts Amazon Show iHeart Show YouTube Music

Deep Dive

Episode live

2026-04-25

Published podcast complete

Charged Alpha | West Pharmaceutical Services Inc. (WST) | S&P 500 Deep Dive — Ep. 217

Quarterly earnings-analysis entry for West Pharmaceutical Services, Inc.. Use the links on the right to open the video or podcast episode.

Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music

Deep Dive

Episode live

2026-04-24

Published podcast complete

Charged Alpha | West Pharmaceutical Services Inc. (WST) | S&P 500 Deep Dive — Ep. 217

Quarterly earnings-analysis entry for West Pharmaceutical Services, Inc.. Use the links on the right to open the video or podcast episode.

Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music